QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 esperion-nominates-esp-2001-as-preclinical-development-candidate-for-primary-sclerosing-cholangitis

– Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associate...

 esperion-announces-proposed-public-offering-of-common-stock-terms-not-disclosed

Esperion Therapeutics, Inc. ("Esperion") (NASDAQ:ESPR), a commercial stage biopharmaceutical company that focuses on de...

Core News & Articles

ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it has entered into a settlemen...

 hc-wainwright--co-reiterates-buy-on-esperion-therapeutics-maintains-16-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...

 esperion-therapeutics-q2-eps-002-beats-014-estimate-sales-82385m-beat-63142m-estimate

Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION